Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Non-Current Debt (2016 - 2021)

Historic Non-Current Debt for Abvc Biopharma (ABVC) over the last 6 years, with Q4 2021 value amounting to $650000.0.

  • Abvc Biopharma's Non-Current Debt rose 42250.8% to $650000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $650000.0, marking a year-over-year increase of 42250.8%. This contributed to the annual value of $650000.0 for FY2021, which is 42250.8% up from last year.
  • Per Abvc Biopharma's latest filing, its Non-Current Debt stood at $650000.0 for Q4 2021, which was up 42250.8% from $104167.0 recorded in Q3 2021.
  • Abvc Biopharma's 5-year Non-Current Debt high stood at $7.7 million for Q4 2018, and its period low was $104167.0 during Q3 2021.
  • For the 4-year period, Abvc Biopharma's Non-Current Debt averaged around $2.4 million, with its median value being $650000.0 (2021).
  • In the last 5 years, Abvc Biopharma's Non-Current Debt plummeted by 9450.38% in 2019 and then soared by 42250.8% in 2021.
  • Abvc Biopharma's Non-Current Debt (Quarter) stood at $7.7 million in 2018, then crashed by 94.5% to $425689.0 in 2019, then tumbled by 70.78% to $124400.0 in 2020, then soared by 422.51% to $650000.0 in 2021.
  • Its Non-Current Debt was $650000.0 in Q4 2021, compared to $104167.0 in Q3 2021 and $315676.0 in Q2 2021.